New radiation drug trial offers hope for tough brain tumors
NCT ID NCT06955169
Summary
This study is testing whether a targeted radiation drug called [177Lu]Lu-DOTATATE can better control progressing brain meningioma tumors compared to standard treatments. About 153 adults whose tumors are growing will be randomly assigned to receive either the new drug or their doctor's choice of standard care. The main goal is to see if the drug helps keep tumors from progressing longer than current options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRACRANIAL MENINGIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baptist Health Medical Group Oncology
RECRUITINGMiami, Florida, 33176, United States
Contact
Contact Email: •••••@•••••
-
Indiana University
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
Contact Email: •••••@•••••
-
Piedmont Healthcare
RECRUITINGAtlanta, Georgia, 30318, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.